MaxCyte Agrees to Acquire Akron Bio

Company MaxCyte; Akron Bio Event Type Acquisition and credit facility Modality Cell-therapy enabling tools and GMP reagents Asset Akron Bio (GMP cytokines, media, plasma-derived materials) Target Not applicable Disease Area Cell and gene therapy manufacturing Summary MaxCyte signed a definitive agreement on November 9, disclosed…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *